Events and Presentations

Corporate Presentation
Pipeline Program Detail
Scientific & Medical Meetings
October 16, 2019
Source
mRNA Medicines to Enable Intracellular, Membrane-Bound, and Extracellular Secreted Therapeutics
October 2, 2019
Source
Phase 1 Trial of an mRNA-based Combination Vaccine Against hMPV and PIV3
June 1, 2019
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (Keynote-603)
June 1, 2019
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (Keynote-603)